✦ LIBER ✦

Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b

✍ Scribed by Yoshimasa Hashimoto; Hidenori Ochi; Hiromi Abe; Yasufumi Hayashida; Masataka Tsuge; Fukiko Mitsui; Nobuhiko Hiraga; Michio Imamura; Shoichi Takahashi; C. Nelson Hayes; Waka Ohishi; Michaki Kubo; Tatsuhiko Tsunoda; Naoyuki Kamatani; Yusuke Nakamura; Kazuaki Chayama

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 174 KB
Volume: 83
Category: Article
ISSN: 0146-6615
DOI: 10.1002/jmv.22028

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Variation at the IL‐28B locus was recently reported to be a significant predictive factor of viral response to pegylated‐interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL‐28B polymorphism rs8099917 and viral and clinical factors were investigated. A total of 288 patients were enrolled who were chronically infected with hepatitis C virus (HCV) genotype 1b and treated with combination therapy. Among them, 87 patients completed 48 weeks of therapy without dose reduction or discontinuation. In multivariate regression analysis, the rs8099917 TT genotype was the only independent factor significantly associated with sustained viral response (P = 0.016, OR 61.5), whereas substitutions at amino acid 70 (aa 70) of the HCV core protein (P = 0.038, OR 5.9) and non‐TT genotypes (P = 0.002, OR 17.2) were associated with nonvirological response. Both factors were also associated with viral dynamics during the initial stage of the therapy. Correlation analysis revealed that rs8099917 genotype was correlated with γ‐glutamyl transpeptidase, hyaluronic acid, and HCV core aa 70. In conclusion, host (IL‐28B polymorphism) and viral (aa 70) factors independently affect response to combination therapy. J. Med. Virol. 83:981–988, 2011. © 2011 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Predictors of viral kinetics to peginter

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b

✍ Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract For chronic hepatitis C virus (HCV) infection, evaluation of response to peginterferon (PEG‐IFN) plus ribavirin (RBV) therapy based on viral kinetics is useful as an early predictor of treatment efficacy, but the underlying mechanisms of the different viral kinetics to treatment are sti

Outcome in partial early virologic respo

Outcome in partial early virologic responders to combination therapy with peginterferon and ribavirin in patients infected with hepatitis C virus genotype 1b

✍ Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Makoto Tanikawa; Yasuhiro Hisan 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB

## Abstract The course and outcome in patients infected with hepatitis C virus (HCV) genotype 1b with partial early virologic response during combination therapy with peginterferon and ribavirin, in whom serum HCV RNA is detectable but has decreased by more than 2 log~10~ 12 weeks after the start o

Impact of weight-based ribavirin with pe

Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1

✍ Ira M. Jacobson; Robert S. Brown Jr; Jonathan McCone; Martin Black; Clive Albert 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 313 KB 👁 1 views

Brass, 14 for the WIN-R Study Group WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PEG-IFN) alfa-2b

Randomized trial of peginterferon alfa-2

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response

✍ Brian L. Pearlman; Carole Ehleben 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB 👁 2 views

Randomized trial of peginterferon alfa-2

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

✍ Maria Buti; Yoav Lurie; Natalia G. Zakharova; Natalia P. Blokhina; Andrzej Horba 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 2 views

The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatm

Predictive factors of virological non-re

Predictive factors of virological non-response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load

✍ Norio Akuta; Fumitaka Suzuki; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; T 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract Patients with high viral load (≥1.0 × 10^5^ IU/ml) of hepatitis C virus (HCV) genotype 1b do not achieve high sustained virological response rates to interferon (IFN)/ribavirin combination therapy. Previous studies suggested that pretreatment amino acid (aa) substitution patterns in the